Tin hat time2 Nov 2022 09:18
This silence from Budd is not seriously worrying. It’s over 7 months since the last investor presentation and since then he hasn’t uttered one word in a direct communication to investors. That’s not good enough by any standards and woeful even by those on AIM. We’ve had a handful of RNSs to which he adds two, at most three, sentences, but we’ve heard nothing on what he has repeatedly stated was his primary focus since three years ago and that is the commercialisation of products for GDR. Obviously things have gone terribly with regard to sales and without sales we have no revenue. We’re at the point it will be very difficult for Budd to do a raise so what’s next? At worst I see the sp dropping to 7 or 8p now on the next RNS - it’s going to be bad and everyone knows it. I don’t see another placing I’m afraid at those low levels. Far more likely GDR becomes a distressed seller and I’m afraid that means we’re could be gobbled up for peanuts. Budd’s sales team is incompetent and has cost a fortune. Big pharmas are patient and will see clearly that GDR is in trouble. Why but now for 30p when you could wait and buy it in 6 months for 10p. Trouble is GDr just doesn’t have the cash to last until revenue comes from AIHl and sales of even this test are not guaranteed! Dreadful management.